Cite

    Touma, Z., Urowitz, M., Gladman, D., Wagner, C., Hsu, B., Chevrier, M., Rose, S., Zhou, B., & Gordon, R. (n.d.). fRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus. Annals of the rheumatic diseases, 77, 705–706. http://access.bl.uk/ark:/81055/vdc_100144725417.0x000058